CureMetrix and Therapixel have entered an agreement to expand access to CureMetrix’s cmAngio and Therapixel’s MammoScreen technologies.
cmAngio is software that reads mammograms and detects and localizes breast arterial calcifications. It analyzes screening mammograms to identify and mark these findings, allowing radiologists to track women who have these calcifications, and, as appropriate, refer them for additional evaluation.
MammoScreen is a breast cancer detection AI system aimed to assist radiologists in reading mammograms. It incorporates 2D, 3D, and prior screenings into its evaluation. MammoScreen generates a report with a scoring system and provides image quality analysis, patient health history alerts, and the ability to generate a draft report.
The companies said that these complementary technologies create a more holistic approach to women’s health and could make mammograms a “two-for-one” exam for women.
